Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class D serine beta-lactamases (often termed OXA-type beta-lactamases) are bacterial enzymes that hydrolyze the amide bond of the beta-lactam ring in penicillins, cephalosporins, cephamycins, monobactams, and for some variants carbapenems, thereby inactivating these antibiotics and conferring resistance. They belong to the serine beta-lactamase superfamily (Ambler molecular class D) that uses an active-site serine for catalysis and are grouped functionally within group 2 serine beta-lactamases alongside class A enzymes. Structural studies of a prototypical member, OXA-10, show an alpha/beta fold related to classes A and C but with distinct active-site features and catalytic base arrangement, indicating a mechanistically distinct serine-dependent hydrolysis pathway within class D. These enzymes likely evolved from DD-transpeptidases (penicillin-binding proteins), the native targets of beta-lactam antibiotics, and enable bacteria—often Gram-negative species that can secrete these enzymes—to survive beta-lactam exposure, driving clinically significant antimicrobial resistance.
Serine-dependent hydrolysis: formation of an acyl-enzyme intermediate via active-site serine followed by deacylation to open the beta-lactam ring and inactivate the antibiotic. Distinct class D catalytic features: class D enzymes share the alpha/beta fold with classes A and C but employ a distinct catalytic base arrangement; structural studies (e.g., OXA-10) indicate differences from class A (Glu166) and class C (Tyr150) general base roles, implying a distinct catalytic mechanism within serine beta-lactamases.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine beta-lactamase class D (OXA-type beta-lactamase).